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Cell death is an essential part of the normal development and
maturation cycle [1], and a homeostatic balance between the rates of
cell proliferation and cell death is critical for maintaining normal
physiological processes. Alterations or deﬁance against these natural
death mechanisms can lead to diseases such as AIDS, diabetes
mellitus, neurodegenerative diseases (such as Parkinson's disease)and cancer, many of which are now, also known to be reactive oxygen
species (ROS)-mediated.
The progressive transformation of normal human cells to malig-
nant derivatives is a complex multi-step process, which requires
dynamic alterations of the genome and successful breaching of
intracellular checkpoints [2]. Extensive research in the cancer ﬁeld has
explored numerous pathways in cancer progression to elucidate
effective measures to target these cancer cells.
Though cancer therapeutics favor a multi-prong approach where
individual treatment varies between surgery, radiation, chemicals,
antibodies and/or cells of the immune system, the effectiveness of the
treatment differs largely between individuals and the cancer
background [3]. In this regard, cancer cells often reside in unique
microenvironments armed with a variety of adaptive responses and
carry mutations, such as defective apoptotic machinery, that further
confer survival advantage. Thus, improving therapeutic efﬁcacy and
selectivity and overcoming drug resistance are the major goals in
developing anti cancer agents today [4].
To fulﬁll these goals, a thorough understanding of apoptotic
signaling pathways and how tumor cells resist apoptosis is impera-
tive, because they provide directions to unravel novel therapies and
key targets to surpass or supplement current cancer treatments. In
this regards, one emerging target is the cellular powerhouse, the
mitochondrion. Before we discuss the signiﬁcance of the mitochon-
dria to cancer therapy, we will review the apoptotic signaling
pathways and how cancer cells resist apoptotic insults.
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Apoptosis is characterized by cell shrinkage, blebbing of plasma
membrane, maintenance of organelle integrity, condensation and
fragmentation of DNA, followed by ordered removal of phagocytes [5].
It works like a “suicide” program and it causes minimal damage to
surrounding tissues. Apoptosis has been subclassiﬁed into two types
of death pathways, namely, the extrinsic pathway and the mitochon-
dria-mediated pathway. These two processes however, are not
exclusive and evidence suggests that they can be linked and that
molecules in one pathway can inﬂuence the other [6]. Moreover,
recent evidences support non-apoptotic roles for many effectors of
the apoptotic signaling pathways. For instance, caspase 2, the most
conserved member of the caspase family, also plays a role in cell cycle
regulation, DNA repair, and tumor suppression [7].
1.2. Extrinsic or receptor-mediated pathway
The extrinsic receptor mediated death pathway requires effective
engagement between the death receptors found on the surface of the
cell membranes and their respective ligands [8] (Fig. 1). The receptor-
mediated pathway involves death receptors from the tumor necrosis
factor (TNF) superfamily such as TNF, CD95 (Fas) and TNF-related
apoptosis inducing ligand (TRAIL) receptors. These receptors have an
extracellular domain to engage the ligands and an intracellular
cytoplasmic domain that is also referred to as the death domain. This
death domain is responsible for transmitting the death signal from the
surface to the intracellular signaling pathways [9]. Activation of CD95
or TNF receptors often leads to receptor clustering and intracellular
recruitment of proteins into a death-inducing signaling complex
(DISC), which then activates an initiator caspase, procaspase 8.
Activated caspase 8 then triggers the execution phase of apoptosis via
the activation of the downstream effector caspase, caspase 3 [10]. The
activated caspases can also induce mitochondrial damage and
reinforce the death signal by facilitating the egress of death amplifying
proteins from the mitochondrial inter-membranous space [11–14].
1.3. Intrinsic or mitochondria-mediated pathway
The mitochondria pathway of cell death can be activated by a
variety of receptor-independent stimuli such as radiation, free
radicals, viral infections and serum/growth factor withdrawal
(Fig. 1). Initially, it was demonstrated that these triggers invariably
result in changes in the inner mitochondrial membrane permeability
due to the opening of the mitochondrial permeability transition
(MPT) pore. The major consequences of this change of permeability
are the loss of themitochondrial transmembrane potential (ΔΨm), the
release of pro-apoptotic proteins and the arrest of the bioenergetic
function of the organelle. The proteins that are released can be broadly
classiﬁed into two categories. The ﬁrst category comprises of proteins
that can activate the caspase dependent pathway. This group includes
proteins such as cytochrome c (cyt c) and Smac/DIABLO (second
mitochondria-derived activator of caspases). The holocytochrome c
induces Apaf-1 oligomerization, leading to the activation of caspase 9.
This active cyt c/Apaf-1/caspase 9 complex forms the apoptosome and
activates the executioner caspases 3 and 7 resulting in the dismantling
of the cell through nuclear fragmentation[10,15,16]. Smac/DIABLO
binds to IAPs (inhibitor of apoptosis proteins) and deactivates them,
thus preventing the IAPs from arresting the apoptotic process,
permitting apoptotic progression. Overexpression of Bcl-2, the
founder oncogene of the Bcl-2 family (see below) has been shown
to block apoptosis in certain cancer cells, which have been classiﬁed as
type II cells, as compared to type I cells in which the execution of
apoptosis program is Bcl-2-independent [8].
The second group includes other pro-apoptotic proteins such as
apoptosis inducing factor (AIF) and endonuclease G (Endo G). In somemodels, the release of these proteins is a late event in apoptosis, which
occurs once the cells are committed to die. Following the release of
AIF, it translocates to the nucleus where it promotes DNA fragmen-
tation. Both AIF and Endo G act in a caspase-independent manner to
execute cell death [17]. For example, in an ovarian stem cell model,
Endo G was shown to mediate caspase-independent cell death in
response to chemotherapeutic agents [18]. Alternatively, AIF has also
been recently proposed to participate in a different form of cell death,
namely programmed necrosis [19].
In the last decade, increasing evidence demonstrated that pro-
apoptotic mitochondrial membrane permeabilization (MMP) could
exclusively affect the outer membrane. This would be achieved via the
formation of lipidic pores or pores formed by members of the Bcl-2
family (discussed below) and then, independent of permeability
transition, affect the inner membrane. It is not known whether the
various modes of MMP can co-exist within a single cell, but it is
plausible that the choice between permeabilization of one membrane
or both depends on the nature of the death stimulus, its intensity and
the cell itself.
2. Regulation of apoptosis
2.1. The Bcl-2 family of proteins
The founding member of Bcl-2 family of proteins, bcl-2, was ﬁrst
cloned in neoplastic B cells with the t (14; 18) chromosome
translocation [20]. Apoptotic events are highly regulated by this family
of proteins, which shares homology in any of the four common Bcl-2
homology (BH) domains. Thus, the Bcl-2 family of proteins has been
divided according to the domains they carry. The anti-apoptotic
proteins, Bcl-2, Bcl-XL, andMcl-1 possess all the four domains (BH1-4).
These proteins also contain a hydrophobic carboxy terminal domain
that enables them to dock onto the outer mitochondria membrane
(OM), the nucleus and ER [21]. It has been shown that Bcl-2 and Bcl-XL
canprotect the cells by interactingwithmitochondrial proteins such as
the adenine nucleotide translocase (ANT) or the voltage dependent
anion channel (VDAC), thus preventing them from forming mito-
chondrial pores, protecting membrane integrity, and inhibiting the
release of apoptogenic factors such as cyt c [22]. More recent evidence
has highlighted novel functional biology of the anti-apoptotic protein
Bcl-2 [23]. Overexpression of Bcl-2 was associated with a slight
increase in steady state intracellular superoxide (O2- ) production,
which was linked to increases in mitochondrial oxygen consumption
and the activity of the rate limiting enzyme in the electron transport
chain, cytochrome c oxidase (COX). Interestingly, pharmacological or
molecular inhibition of the NADPH oxidase restored apoptosis
sensitivity of Bcl-2 overexpressing cells, thus implicating the pro-
oxidant activity of Bcl-2 in its anti-apoptotic function.
The second category of Bcl-2 family of proteins contains BH
domains 1, 2 and 3. These proteins would include Bax and Bak. Bax is a
pro-apoptotic protein that resides in the cytosol under physiological
conditions. An apoptotic trigger however, can lead to its translocation
to themitochondria and its subsequent insertion into the OMM. At the
mitochondria, Bax can homodimerize or heterodimerize with other
pro-apoptotic members such as Bak or truncated Bid, thus disrupting
the integrity of the OMM by forming mitochondrial pores and
increasing its permeability. These pores can then lead to the release
of apoptogenic factors such as cyt c [24]. Some reports have also
suggested that Bax engages in a close molecular cooperation with
proteins from the PTPC, such as ANT and/or VDAC, to induce
mitochondria membrane permeabilization (MMP) [25]. Bcl-2 and
Bcl-XL have been shown to antagonize the apoptotic cascade by a
direct interaction and sequestration of these pro-apoptotic proteins
[26]. Similarly Bak, which is normally inhibited by its interaction with
VDAC, can also homodimerize and result in pore formation at the
mitochondria when freed.
Fig. 1. The extrinsic and intrinsic pathways of apoptosis: Death receptor pathway (left) is initiated by the ligation of the ligands to their respective surface receptors. This leads to
receptor oligomerization and DISC formation, which then triggers a caspase activation cascade that result in detrimental modiﬁcations at the cytosol, membrane and nucleus. Where
caspases cannot be activated, cell death is seen to resemble necrosis and is termed necroptosis. The intrinsic pathway (right) is activated by multiple stimuli (grey box), which
converge at the mitochondrion and induce mitochondrial membrane permeabilization (MMP) and subsequently result in the release of pro-apoptotic mitochondrial proteins into
the cytosol. This activates caspase-dependent and caspase-independent processes culminating in cell death. MMP hampers mitochondrial function, which triggers a bioenergetic
crisis due to loss of ATP, ROS production and pH alterations. Depending on the intensity of the mitochondrial insult, the cell can undergo apoptosis, necrosis and/or autophagic cell
death. Both the intrinsic and extrinsic pathways can be inhibited by proteins such as Bcl-2 and cIAP1/2 promoting cell survival. AIF: apoptosis inducing factor; cIAP1/2: inhibitor of
apoptosis protein; C, caspase; z-VAD, pan-caspase inhibitor.
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proteins. The BH3-only family members include Bim, Bad, Bmf, Noxa
and Puma. They act by neutralizing the anti-apoptotic proteins [27].
For instance, Bim, Puma, Bad and Bmf heterodimerize with Bcl-2 and
Bcl-XL and sequester them, thereby blocking their anti-apoptotic
action at the mitochondria.
2.2. Inhibitors of apoptotic proteins
Cell fate is tightly regulated by the interactions between pro and
anti-apoptotic proteins which act to tweak the balance between
survival and cell death [27]. In cancers, the crippling of pro-apoptotic
pathways or enhancement of the anti-apoptotic pathways via the
modulation of the regulatory proteins largely confers survival
advantages onto the cells in the face of death triggers.
The inhibitors of apoptosis (IAPs) family were ﬁrst identiﬁed in
baculovirus and to date, eight mammalian IAPs have been described
[28]. This would include neuronal apoptosis inhibitory protein (NAIP),
cellular IAP1 and IAP2 (cIAP1 and cIAP2), X-linked inhibitor of apo-
ptosis (XIAP), Survivin, Testis-speciﬁc IAP (Ts-IAP), BIR-containing
ubiquitin conjugating enzyme (BRUCE) and Livin [29]. IAPs are
characterized by the presence of 70–80 amino acid baculoviral IAP
repeat (BIR) domain(s), which are important for the binding and
inhibition of caspases. They play a critical role in blocking cell death by
regulating the caspase cascade, and then, may inﬂuence both the
intrinsic and extrinsic pathway in the cells.
Of the IAPs, XIAP has been best described, possibly due to the
extensive studies on its anti-apoptotic role and the plausible
therapeutic beneﬁts in targeting it. XIAPs have been shown to
antagonize the apoptotic cascade via the direct inhibition of caspases
and via proteasome-dependant degradation of caspases. In addition to
these caspase inhibitory roles, it has also been found to activatenuclear factor kappa B (NF-κB) by promoting the nuclear localization
of NF-κB.
IAPs have been shown to be regulated by IAP binding proteins such
as second mitochondrial activator of caspases (Smac/DIABLO) [30].
Smac/DIABLO normally resides in the mitochondria and upon
receiving an apoptotic stimulus via the intrinsic pathway is proteo-
lytically cleaved and released into the cytosol through the Bax/Bak
channels or via Bid-induced permeabilization of the outer mitochon-
drial membrane. Subsequently, Smac/DIABLO associates with IAPs
and prevents them from inhibiting caspases, thus promoting
apoptosis.2.3. The tumor suppressor P53 and P63/P73
P53, also known as the “guardian of the genome” [31] has been
shown to play a critical role in intrinsic tumor suppression via two
mechanisms. This would include cell cycle arrest and induction of
apoptosis. A variety of triggers such as DNA damage, oncogene
activation, and telomere erosion can lead to the activation of p53.
DNA damage can be due to exposure to radiation or drugs.
Subsequently this damage signals the activation of the cellular
checkpoint kinases such as ATM (Ataxia telangiectasia mutated) and
ATR (ATM and Rad3-related), which then leads to the phosphoryla-
tion of p53. P53 is normally sequestered byMdm2. Phosphorylation of
p53 disrupts p53's interaction with Mdm2 and ushers its activation
[32,33]. P53 then holds the cell at a checkpoint until the damage is
repaired. If the damage is irreversible, apoptosis is triggered.
Oncogenes such as MYC, RasV12 and E2F-1 have also been shown to
induce apoptosis by indirectly activating p53 via activation of ARF
(Alternative Reading Frame) [34]. ARF acts by sequestering Mdm2
thus releasing p53 [35].
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dependent and -independent manner [36]. In the transcription
dependent pathway, p53 activates the expression of several pro-
apoptotic proteins such as PUMA, Bax and BID, which are involved in
the regulation of the intrinsic cell death pathway as well as
upregulates CD95 (Fas/Apo1) and DR5 receptors, which mediate the
extrinsic cell death signals. In addition to transcriptional activation of
pro-apoptotic proteins, p53 has also been shown to suppress anti-
apoptotic proteins such as Survivin [37].
In the transcription-independent pathway, it has been shown that
a fraction of p53 localizes to the mitochondria following apoptotic
stimuli where it physically interacts with Bcl-2 and/or Bcl-XL and
antagonizes their anti-apoptotic function at the outer mitochondrial
membrane. This interaction frees Bax and Bid to elicit their
downstream effects. Moreover, p53 has also been shown to interact
with Bak thus releasing it from the neutralizing hold of Mcl-1 [38]. In
addition to the effects of themitochondria localized p53, cytosolic p53
has also been reported to induce the activation of Bax in a
transcription-independent manner, thereby leading to mitochondrial
membrane permeabilization and cyt c release [39–42].
Thus, irrespective of being transcription-dependent or -independent
p53 activities, they both elicit their effects at the mitochondria. While
nuclear p53 via its transcriptional activity induces expression of Bax,
PUMA, Noxa [43] and Bid, cytosolic or mitochondrial p53 via
transcription-independent mechanisms directly activates Bax/Bak and
neutralizes the anti-apoptotic effect of Bcl-2/Bcl-XL at themitochondria.
Twoothermembersof thep53 family, p63 andp73, play a role in normal
development in a tissue speciﬁc manner. Though these homologues
share a remarkable degree of structural similarity, they display
considerable functional diversity [44]. Despite the structural homology,
mutations of p63 and p73 are rarely associated with human cancer,
however, in tumorigenesis the net effect of these homologues is
suggested to be a function of the relative expression of their multiple
protein isoforms, regulated by transcriptional and post-translational
mechanisms [45,46].2.4. Inﬂuence of ROS on cell death signaling
Even though ROS does not act directly through the death
receptors, it can inﬂuence the extrinsic death pathway by altering
the intracellular milieu, making the environment conducive for
effective engagement between receptors and ligands or the execution
of the downstream events leading to apoptosis. Receptor upregulation
has been observed in several systems with exogenous ROS or ROS
inducing agents. Upregulation of CD95 and TRAIL death receptors
have been observed in response to hydrogen peroxide (H2O2) [47]. In
addition, intracellular ROS induced by treatment with cisplatin also
promoted surface clustering of CD95 and treatment with antioxidants
abolished this clustering [48]. ROS has also been shown to sensitize
cancer cells to TRAIL-induced apoptosis [49]. The induction of
intracellular ROS following treatment with TRAIL has also been
shown to result in caspase activation, which pushes the cell further
toward execution [50]. Caspases are critical downstream execu-
tioners, which work most effectively under reducing conditions. As
such, proteins that can antagonize a surge in cellular ROS levels
following exposure to ROS inducing triggers can protect cancer cells
from ROS mediated apoptosis. In this regard, it has been recently
shown that hTERT overexpression in cancer cells alleviates cellular
ROS levels by way of potentiating the cellular anti-oxidant defense
systems and altering mitochondrial activity, thus conferring survival
advantages onto cancer cells against ROS mediated death stimuli
[51,52].While high levels of ROS have been deemed to be detrimental,
exposure of cells to a slight pro-oxidant state has been shown to result
in the oxidation of caspases at the catalytic cysteine residues ren-
dering them ineffective and the cells resistant to caspase-dependentapoptotic triggers [53,54]. Thus, ROS can play a dual role with regards
to apoptosis by modulating the cellular micro-environment [55–57].
The intrinsic pathway of cell death is especially susceptible to ROS.
Previously, it has been shown that exogenous addition of H2O2 has an
inhibitory effect on Na+/H+ exchanger activity resulting in cytosolic
acidiﬁcation, which creates a conducive environment for apoptosis
[58,59] and similarly, exposure of cells to the experimental drug C1
has also been shown to trigger intracellular H2O2 production, which
causes intracellular acidiﬁcation. This change in cytosolic pH in-
ﬂuences the conformational status of Bax, resulting in its activation
and oligomerization at the mitochondria, thereby facilitating the
release of apoptosis ampliﬁcation factors from the mitochondrial
inter-membranous space [60,61]. The inner mitochondrial protein,
ANT, is also a target of ROS modulation by virtue of its redox-sensitive
cysteines, providing an additional mechanism by which drug-induced
ROS productionmay activate mitochondrial apoptosis [62]. Moreover,
superoxide radical (O2−) has also been shown to modulate the
function of the OM protein, VDAC, to facilitate Cyt.C release [63].
Finally, ROS can directly modulate protein complexes within the
mitochondrial electron transport chain, activate caspases and trigger
cell death [64]. Other targets of ROS withinmitochondria remain to be
identiﬁed, but based on the pivotal involvement of the mitochondria
in energy supply, lipid biosynthesis, as well as detoxiﬁcation, it is
highly probable that oxidative modiﬁcation of these targets could
affect cell fate.
3. The problem of death resistance
Surgery, radiation and chemotherapy have been the conventional
therapies in cancer treatment. Different combinations of these
treatments have been used to largely improve disease prognosis and
combat cancer. However, the evolution of adaptive mechanisms
provides cancer cells with the ability to evade apoptotic execution and
bestows upon them a survival advantage.
3.1. Upregulation of pro-survival proteins
Upregulation of the anti-apoptotic family of proteins has been a
frequent explanation for the resistance observed in cancer cells.
Increased expression of the anti-apoptotic family members such as
Bcl-2, Bcl-XL and Mcl-1 has been often observed in cancer cells [65],
where they serve to antagonize mitochondria-mediated cell death
pathway. Speciﬁcally, Bcl-2/Bcl-XL upregulation is clearly associated
with poor prognosis in cancer [66]. The ability of these proteins to
antagonize the pro-apoptotic family of proteins such as Bax and Bak
has been the key mechanism by which these cells acquire resistance
to apoptosis. As such, measures to target Bcl-2 or Bcl-XL via anti-sense
oligonucleotides have been employed in clinical studies to sensitize
cancer cells to apoptotic triggers [67,68]. However, as eluded above
there is emerging evidence to support a novel mechanism of death
inhibition by Bcl-2 involving its ability to modulate cellular redox
status and mitochondrial metabolism.
As described earlier, IAPs are a class of anti-apoptotic proteins
upregulated in a variety of human cancers. IAPs inhibit the activity of
caspases and hence protect cells from the deleterious effects of active
caspases. Smac/DIABLO, a natural antagonist of IAPs, has been shown
to sensitize cells to drug- and receptor-induced apoptosis by binding
to XIAP and releasing caspase-9 in vitro.
In addition to the upregulation of anti-apoptotic proteins, activation
of pro-survival paths such as PI3K-Akt pathway further helps to resist
death triggers. Following stimulation by growth factors or cytokines,
phosphatidylinositide-3-OH kinase (PI3K) is activated and phosphory-
lates phosphoinositides. Phosphatidylinositol 4, 5-bisphosphate 3
activates the kinase 3-phosphoinositide-dependent protein kinase-1,
which in turn activates the kinase Akt by phosphorylation at two key
regulatory sites. Once activated, Akt phosphorylates its target substrates
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which results in NFκB activation that promotes survival and Bad
phosphorylation resulting in Bad inactivation and blocking of the
apoptotic signal. In addition, phosphorylation of caspase 9 also blocks
the induction of apoptosis [69].
Increased resistance to drugs that activate the extrinsic death
pathway has also been observedwith upregulation of proteins such as
c-Flip and decoy receptors. c-Flip inhibits the autoproteolytic cleavage
of pro-caspase 8, which is involved in DISC formation, and hence, the
downstream transduction of the death signals via the extrinsic death
pathway [70]. Decoy receptors can compete with death receptors for
the ligands such as TRAIL and CD95, thus inhibiting/abolishing death
signal transduction (reviewed in [71]). Thus cells with higher
expression of decoy receptors or with mutant death receptors that
retain their ability to bind the death ligand while lacking the ability to
engage the downstream processes such as DISC formation are more
resistant to the extrinsic apoptotic triggers.
3.2. Suppression of pro-apoptotic proteins
In addition to the upregulation of pro-survival factors, suppression
of pro-apoptotic proteins also contributes to resistance against
apoptosis-inducing therapeutic regimens. Thus, Bax is one key pro-
apoptotic member that is frequently suppressed or mutated in
cancers. The mutations include frameshifts and/or mutations at the
BH domains, which lead to a loss of function. Indeed tumors with
reduced Bax expression have been found to have a poorer prognosis
[72,73]. In addition to Bax deﬁciencies, it has also been reported that
Bak deﬁciencies can also lead to substantial inhibition of mitochon-
dria-mediated apoptotic cell death. The activation of Bax and Bak is
mediated via caspase 8-induced cleavage of the BH3 only protein Bid
to tBid. Activation and oligomerization of BAX or BAK have been
proposed to result in the formation of a VDAC-containing pore and
permeabilization of mitochondrial membranes. This leads to the
release of cyt c and the subsequent engagement of the Apaf-1-
caspase-9 apoptosome complex, which activates downstream effector
caspases. In this regard, suppression of components which act
downstream of the mitochondria such as cyt c, Apaf-1 and caspases
can protect the cells from apoptotic insults. Accordingly, the
expression levels of several pro-apoptotic members of Bcl-2 family,
such as Bim and Puma have been shown to correlate with colon
carcinoma susceptibility to chemotherapy [74].
Silencing death receptors is another common strategy employed
by cancer cells to protect them from death receptor-induced
pathways (CD95 and TRAIL). Besides downregulation, death receptors
can also be mutated such that even if the ligands can bind [77], they
may still be unable to engage the intracellular apoptotic signaling
pathway. The mutations include point mutations in the cytoplasmic
death domain of CD95 and/or deletion that leads to a truncated form
of the death receptor. Moreover, deletions and mutations of the death
receptors TRAIL-R1 and TRAIL-R2 have also been observed in tumors
[75,76].
3.3. Defects in p53 signaling pathways
P53 is the most commonly mutated tumor suppressor gene in
human cancers. In addition to the loss of tumor suppression function
and exertion of dominant-negative effects over the remaining wild-
type protein, several p53 mutants can also actively regulate cancer
development and progression [77]. Similarly, modulation of the
regulators of p53 can also contribute to genome instability and
apoptosis resistance. One such modulator is p19 ARF, which when
activated by oncogenic stress facilitates p53 stabilization. As such,
besides defects in p53, deﬁciencies in ARF have been shown to result
in protection for tumors with wild-type p53 [78]. Additionally,
upregulation of the p53 inhibitors MDM2 and/or MDM4 also leadsto p53 degradation, thus offering further protection from cytotoxic
insults [79].
4. Targeting the mitochondria as a novel strategy for
cancer therapy
Though targeting the inherent adaptive anti-apoptotic strategies
enhance sensitization of cancer cells to therapeutic regimes, the rise of
resistance in cancer cells poses a challenge for scientists and
physicians. In this regard, numerous anticancer agents target
pathways that lie upstream of the mitochondria, which then converge
onto the intrinsic death pathway. However, the deregulation of
several master switch proteins such as HIF1, HKII, c-Myc and P53,
leads to resistance in these cells. Thus, directly targeting the
mitochondria may allow us to overcome the problem of resistance
that arises from engaging the upstream pathways [4].
The mitochondria are the cellular powerhouses and hence the
primary source of energy for the cells. Since cancer cells generally
display a higher energy demand, targeting the cellular energy source
seems to be an attractive solution. ATP is the energy currency of cells
and a high ratio of ATP/ADP is produced primarily by the oxidation of
glucose. Oxidation of glucose is a two stage process namely, glycolysis,
which is the ﬁrst stage, that occurs at the cytosol and oxidative
phosphorylation, the second stage that occurs at the mitochondria,
wheremost of the ATP is produced. In addition to the pertinent role in
cell survival, the mitochondria are critical regulators of the intrinsic
pathwayof apoptosis [80]. They control several death effector cascades
through the release of pro-apoptotic proteins such as Apaf-1, cyt c and
Smac/DIABLO, which normally reside in the inter-membranous space.
Thus, the convergence of these life and death regulatory roles at the
mitochondria has made it a highly favorable target for therapeutic
manipulation.
4.1. Cancer cell mitochondria
Therapeutic targeting of cancer cells have often relied on the
inherent differences between normal cells and transformed cells,
which allow for manipulation, better selection, and eradication of
these cancer cells. In this regard, one of the main traits of cancer cells
is their ability to proliferate rapidly and survive well under hypoxic
conditions. This differential behavior has been reported as an outcome
of altered metabolic efﬁciencies and/or mitochondrial functions,
which will be discussed further in the sections below.
4.2. Altered bioenergetics of cancer cells
Rapidly proliferating cancer cells have a higher energy demand
that needs to be met amidst an oxygen-deprived environment. The
search to ﬁnd the mechanisms by which cancer cells meet their
energy requirement led to the ﬁndings by Otto Warburg [81] in 1926,
and subsequently to the Warburg hypothesis that cancer cells derive
most of their energy from glycolysis even under aerobic conditions,
and that cancer is an outcome of defective mitochondrial energy
metabolism. Since then, many theories have risen to challenge this
hypothesis and question if the impaired mitochondrial metabolism is,
indeed, the cause or an effect of transformation, given the other
pertinent factors involved in the process of carcinogenesis [82,83]. In
this regard, it is possible that upregulation of glycolysis could be an
adaptive response of cancer cells to increase ATP production in an
oxygen deprived environment. This shift in bioenergetics has also
been suggested to confer tumor cells with additional mechanism of
resistance as it transforms the intracellular milieu into a more acidic
environment, conducive for invasion of surrounding tissues [84]
(Fig. 2). Additional causes contributing to promote the resistance of
mitochondria toward pro-apoptotic permeabilization reside in the
downregulation of pro-apoptotic factors (e.g. ions, proteins, ROS) and
MMP
HIF1α
PTPC
HKII
BCL-2
BAX
OXPHOS
ATP
Glucose
Glucose 6-P
Pyruvate
ATP
Glucose Resistant mitochondria
Downregulation:  
calcium, 
ROS, Bax, CypD
Upregulation: 
Bcl-2, ANT2
HSP, SOD, Catalase, GST
Apoptosis
Low OXPHOS  
High glycolysis
Metabolism
Hypoxia  02
Fig. 2. Apoptosis-resistant mitochondria and cancer. Resistance to mitochondrial membrane permeabilization (MMP) is a common phenomenon observed in cancer cells. It often
arises from blocking the permeability transition pore complex (PTPC) opening or due to the failure of pro-apoptotic BAX/BAK activation by anti-apoptotic BCL-2 family members. As
a result, the release of pro-apoptotic proteins from the mitochondrial intermembrane space is inhibited. Resistance also arises from the down regulation of pro-apoptotic factors
(proteins or second messengers such as calcium and reactive oxygen species (ROS)) and up-regulation of anti-apoptotic proteins, thus tilting the balance toward survival. Moreover,
alterations in mitochondrial bioenergetics and hence the switch in energy supply from oxidative phosphorylation (OXPHOS) to glycolysis, along with conditions such as hypoxia can
also contribute to MMP resistance. O2: oxygen.
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ones, anti-oxidant enzymes …) (Fig. 2).
Though the reasons behind the glycolytic shift and the glucose
addiction has yet to be fully unfolded, it is now known that this
observation transcends across all malignancies, a trademark that is
being utilized today in cancer diagnostics such as PET scans [85].
Positron emission tomography (PET) utilizes radioactive glucose
molecules and provides a dynamic image of the body's interior based
on the rates of glucose metabolism; a trait that is distinctly ampliﬁed
in cancer cells. In the years following the postulation of the Warburg's
hypothesis, the discovery of numerous critical cancer regulators, such
as the p53 protein and other tumor suppressors or oncogenes have
shifted focus away from themitochondria. In the last decade however,
a renewed interest has returned to the role of mitochondria and
energy metabolism in cancer.
In addition to the increased glycolysis, the altered bioenergetics ob-
served in many human carcinomas has been highly correlated with the
downregulation of the catalytic subunit of the mitochondrial H+ATP
synthase (β-F1-ATPase) [86]. Analysis of mitochondrial and glycolytic
phenotypes in cancer cells and normal cells has also resulted in a
bioenergetic signature, consistent across several types of human
carcinomas including breast, colon and stomach. In this regard, Cuezva
et al. deﬁnedabioenergetic indexof the cell (BEC)basedon the levels of a
bioenergetic marker of mitochondria relative to a cellular glycolytic
marker [87]. The relative levels were assessed in tissue biopsies via
immunohistochemical staining or immunoblotting. Their observations
demonstrated that BEC index served as a reliable indicator along with
the expression of β-F1-ATPase in breast, gastric, lung and esophageal
cancers.
Another important cause of resistance of cancer cells to apoptosis,
linked to the metabolic reprogramming of cancer cells, is the
enhanced association of hexokinase with mitochondrial porin,
VDAC. This has been suspected to affect VDAC pore opening and to
limit the association of pro-apoptotic members of the Bcl-2 family
(e.g. Bax, t-Bid) with VDAC and hamper mitochondrial permeabiliza-
tion and cyt c release [88] (Fig. 2).
4.3. Perturbation of the mitochondrial DNA in cancer cells
In aerobic cells, mitochondrial respiration is one of the major
sources of ROS. In the mitochondrial electron transport chain (ETC),
there is a sequential transfer of electrons (e-) with cytochromeoxidase (COX) being the terminal acceptor, which reduces bound O2
to water [89]. During this process of electron transfer, some electrons
may leak onto oxygen and lead to the formation of ROS. Indeed, it has
been estimated that at physiological oxygen levels, 1–4% of oxygen
might be incompletely reduced to O2•− [90,91]. One key target of ROS is
mitochondrial DNA (mtDNA), which encodes critical proteins of the
ETC. The lack of protective histones around the mtDNA, limited DNA
repair mechanisms found in the mitochondria, and the close
proximity to the ROS generating ETC, makes the mtDNA more easily
prone to ROS-induced DNA damage.
Defective mtDNA that translate into defective mitochondrial
components can further aggravate mitochondrial dysfunction by
accelerating aberrant ROS production and inefﬁcient ATP generation.
This can then result in oxidative damage of cellular DNA and proteins
thus setting in motion, a vicious cycle of events [92]. As such, the
mutations incurred due to oxidative damage either sensitize the cells
to death signaling or confer survival advantage by altering cellular
response to apoptotic stimuli, and the expansion of these surviving
populations could give rise to resistant clones.
4.4. Morphological and physiological differences
The morphological differences observed in the mitochondria vary
between tumor cell lines in terms of size, shape and count. It has been
noted that the mitochondria in rapidly growing tumors tend to be
fewer in number and smaller and have fewer cristae then slow
growing tumors, normal cells or well differentiated tumors [93]. In
addition, differences in the IM composition have also been observed
between normal and transformed cells [94]. Interestingly, studies
have also shown that the mitochondrial membrane potential is
approximately 60 mV higher in carcinomas as compared to their
normal controls [95].
5. Riding on mitochondrial dysfunctions to target cancer cells
The mitochondria are at the crossroads of life sustaining and death
inducing paths. As such, it is an attractive option to be targeted to
restore normalcy in defective cells and abrogate progression to
malignancy. Alternatively, given the stark differences the mitochon-
dria present in cancer cells, riding on its dysfunctions could help to
select and sever the lifeline to these cancer cells.
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Mitochondrial DNA mutations are often found in a variety of
cancers including lung, ovarian, thyroid, colon, gastric, brain, bladder,
head and neck and breast. Interestingly, the mutations are homo-
plasmic in nature and this has often been attributed to the clonal
selection of cancer cells, and alternatively to unbiased mtDNA
replication and sorting during cell division. As an outcome all the
mtDNA in a cell and in a tumor express the same mtDNA mutations
[96]. These homoplasmic mutations have much diagnostic value, as
they are easily detectable in body ﬂuids such as blood, saliva and
urine. Due to its abundance and dominance in cancer cells, it may also
be a possible option worth exploring as a molecular marker of cancer
[97]. Given the immense impact mtDNAmutations has in determining
cellular transformation coupled with the lack of efﬁcient repair
mechanisms at the mitochondria, research in the areas of DNA repair
and maintenance at the mitochondria might provide valuable tools,
which could help repair and/or protect mitochondrial genome from
impending damage [98,99].
5.2. The switch in energy metabolism
Though maintenance of the intracellular pH at an optimal level is
critical for the functioning of many enzymes and cellular processes,
the high metabolic activity and glycolysis in cancer cells results
in elevated levels of lactate production and the change in the
intracellular pH activates membrane pH regulatory pumps, such as
the Na+/H+antiporter (NHE), to actively extrude H+ions leading to
an acidic extracellular and an alkaline intracellularmilieu. To that end, a
number of reports have demonstrated increased activity of the NHE-1
exchanger in cancer cells, which correlated with cellular sensitivity to
apoptosis. In addition, the cellular uptake of chemotherapeutic drugs
may alsobealtered by the changes in thepHgradient [100,101]. As such,
drugs that may perturb the intracellular pH gradient could potentially
modify cellular responses to the chemotherapeutic agents. In this
regard, treatment with proton pump inhibitors (PPI), which acts by
irreversibly binding to the proton pump and inhibiting proton
translocation and acidiﬁcation of the extracellular environment has
been shown to reverse drug resistance in chemoresistant melanoma
cancer cells and sensitize multi-drug resistant cells to cytotoxic drugs
[102,103].
5.3. The energy supply
Since cancer cells display a high energy demand, drugs that can
directly perturbmitochondrial respiration and glycolysis could lead to
an extensive depletion of ATP, sensitizing cancer cells to death. In this
regard, Sahra et al. demonstrated that treatment with 2-deoxyglucose
(2DG), a potent inhibitor of glucose metabolism via the inhibition of
hexokinase and metformin, a widely used anti diabetic agent that
inhibits oxidative phosphorylation, induced massive reduction in cell
viability in LNCaP prostate cancer cells as compared to normal
prostate epithelial cells by depletion of cellular ATP [104].
Another drug that has been shown to block aerobic glycolysis in
cancer cells, possibly by inhibiting hexokinase, is lonidamine (LND),
which is derived from indazole-3-carboxylic acid. LND disrupts
energy metabolism in cells resulting in ATP depletion, and in addition,
leads to an accumulation of lactate in the cells [105,106]. This drug is
now being used in combination therapy to sensitize cancer cells to
conventional chemotherapeutic drugs such as cisplatin at lower doses
[97,98,107,108]. Its prospects are also being reviewed in Phase III
clinical trials [109].
Highmetabolic rates andmitochondrial dysfunction has been shown
to lead to elevated intracellular ROS levels in cancer cells. Thus anti-
cancer compounds that push the cellular ROS levels past the threshold for
cancer cells are potent inducers of apoptosis. Pelicano et al. adopted acombinatorial treatment strategy involving 2-methoxyestradiol (2-ME),
which inhibits SOD and results in O2− accumulation, with arsenic tri-
oxide (As2O3) resulting in inhibition of mitochondrial respiration and
increased O2− production in leukemia [110]. Similar death sensitizing
effects of drug-induced ROS production have been reported with small
molecule compounds LY30 [111,112], C1 [113], and resveratrol [114].
Along similar lines, itwas recently shown that the smallmolecule orphan
drug, dichloroacetate (DCA), reversed the metabolic reprogramming
observed in the ex vivo glioblastoma model by targeting pyruvate
dehydrogenase kinase II. DCA triggered cell death in cancer cells by
inducing mitochondrial membrane depolarization and increased mito-
chondrial ROS production [115].
5.4. Mitochondria membrane permeabilization
The mitochondria is enveloped in two membranes commonly
referred to as IM and the OM [116]. The IM surrounds the inner
mitochondrial matrix and is folded into the numerous cristae, while
the outer mitochondrial membrane surrounds the inner membrane,
thus creating the intermembrane space. The intermembrane space is
where many of the pro-apoptotic proteins such as Cyt. C, Smac/
DIABLO and AIF are localized. In healthy cells, the IM is impermeable
to ions [117], which allows the ETC to actively build up the proton
gradient across the IM. The ΔΨm results from the difference in
electrical potential generated by the electrochemical gradient across
the IM. This proton gradient is then used to drive ATP synthesis via
ATP synthase that is located at the IM. As such, the maintenance of the
proton gradient is imperative for survival and is a tightly regulated
mechanism [117–119].
Of interest, the mitochondrial membrane potential is often found
to be elevated in cancer cells. This negative transmembrane potential
found on the inside of themitochondria allows themitochondria to be
targeted using positively charged ions such as the delocalized
lipophilic cations (DLCs), which accumulate in the mitochondria.
DLCs are toxic to the mitochondria at higher concentrations. Thus
their selective accumulation in the mitochondria of carcinomas,
which display an increased mitochondrial membrane potential,
allows for targeted elimination of these cancer cells [95,120]. One
such compound is MKT-077, which accumulates in the mitochondria
in a potential-dependent manner to inhibit respiration and growth
[121]. However, the development of this compound was discontinued
after results of phase I clinical trials indicated renal toxicity.
5.5. The permeability transition pore
The PTPC is a high conductance channel formed by the association
of several mitochondrial proteins. Its composition is still unknown
and could vary depending on the tissues. Previously, PTPC composi-
tion has been proposed to include VDAC, ANT and cyclophilin D
(Fig. 3). ([122,123]. Under physiological states, this complex is kept
closed and can open in a voltage-dependent and dynamic manner.
The additional PTPC interacting proteins would include peripheral
benzodiazepine receptor that is localized at the outer mitochondria
and kinases such as hexokinase and creatine kinase [117,123,124].
Physiological factors such as ROS, changes in pH and association
with proteins such as Bax induce a conformational change resulting in
the opening of the pore and the sudden increase in the permeability of
the IMM brings about the dissipation of ΔΨm. This then leads to a
rapid swelling of the matrix that has a high solute content and the
subsequent rupture of the OMM and release of the intermembrane
space proteins [118,125].
Thus drugs that can disturb PTPC would allow for direct targeting
of the mitochondria and help circumvent the problem of apoptosis
resistance upstream of the intrinsic mitochondrial pathway. More-
over, differences in the composition of PTPC and the critical
interacting proteins within the complex have been reported between
Fig. 3.Mitochondria: promising targets for cancer chemotherapy. Permeability transition pore complex (PTPC) and Bcl-2 family members can be directly targeted by (1) second
messengers such as calcium and ROS originating from the endoplasmic reticulum (ER), plasma membrane (NADPH oxidase; NOX) and oxidative phosphorylation (OXPHOS);
(2) endogenous tumor suppressor proteins or derived peptides, (3) viral proteins or derived peptides and (4) small molecules. Indirectly, MMP could be favored bymodulation of
gene expression ormetabolic reprogramming to activate OXPHOS and decrease glycolysis. ANT: adenine nucleotide translocase; VDAC: voltage-dependent anion channel; CypD:
cyclophilin D; TSPO: Translocator protein; HKII: hexokinase II.
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ANT showed that the transcript levels were shown to be different
between the tumor and transformed cell lines. In particular, ANT2
gene was found to be upregulated in oncocytomas and renal tumors
[126]. Apart from ANT, the levels of peripheral benzodiazepine
receptor (PBR), hexokinase II and mitochondrial creatine kinase
have also been found upregulated in some tumors [127,128]. In an
attempt to target the ANT, several ANT ligands have been used to
induce or prevent mitochondrial apoptosis [129]. These ANT-based
drugs will largely aim to convert the ANT into non-speciﬁc pores [22]
or to inhibit its ADP/ATP exchange function [130]. Other drugs include
PK11195, an antagonist of the PBR. PK11195 displays high binding
afﬁnity to PBR and has been shown to contribute to a decrease in ΔΨm
and cyt c release. Its anti-tumor effects have now been tested in
combination with a variety of cytotoxic and chemotherapeutic agents
in various human tumor cell lines [131].5.6. The members of the Bcl-2 family
As described in the earlier sections of this review, the Bcl-2 family
of proteins plays a critical role in switching the balance between
survival and death largely by regulating MMP. In that light, Bax and
Bak have been shown to regulate the ANT and VDAC channels, altering
the mitochondrial functions such as causing ANT to open and VDAC to
close resulting in matrix swelling and outer mitochondrial membrane
disruption [22,132]. The anti-apoptotic proteins Bcl-2 and Bcl-XL on
the other hand have been shown to directly interact with VDAC and
elicit a protective role at the mitochondria [133]. Bcl-xl binds with
VDAC1 and prevents the closure of the channel, hence maintaining
the ATP/ADP exchange, preventing mitochondrial hyperpolarization,
matrix swelling and rupture [134].The altered ratios favoring the pro-survival proteins such as Bcl-XL
and Bcl-2 over the pro-apoptotic proteins such as Bak and Bax have
been shown to lead to chemoresistance in cancer cells. The need to
drive the ratio toward death in cancer cells has led to the development
of anti-cancer compounds that can either act to suppress the pro-
survival proteins such as Bcl-2 and Bcl-XL, ormimic the pro-death BH3
only proteins such as Bid, Bim, Bad, Bmf, Noxa and PUMA to promote
cell death. In this regard, HA14-1 was one of the ﬁrst small-molecule
Bcl-2 inhibitors to be reported. This synthetic chromene molecule
works by displacing Bax and hence releasing it from Bcl-2's inhibition,
resulting in apoptosis. Of value, it has been shown to overcome
radioresistance and chemoresistance in several cancer models
including glioblastoma, prostate cancer and leukemia [135,136].
Another attractive drug target is the naturally occurring Bcl-2
inhibitor gossypol, which is derived from cottonseeds [137]. Gossypol,
like HA14-1 was also shown to bind to the BH3 domain of Bcl-2. The
anti-apoptotic effects of Gossypol have been demonstrated in head
and neck cancer, colon, prostate, pancreatic and leukemia cell lines
[138–140]. Unfortunately, the general toxicity and undesirable
pharmacological properties it presented halted its progress in clinical
development. More promisingly, an antisense strategy to down-
regulate Bcl-2 and restore death sensitivity is currently under clinical
evaluation for the treatment of melanoma [141].
While drugs that could suppress anti-apoptotic proteins have
yielded some promising results, attempts to increase sensitivity by
mimicking the structures of pro-apoptotic proteins has also led to the
discovery of some novel BH3 mimetics (Fig. 3). One such well
understood BH3 mimetic is ABT-737. ABT-737 mimics the BH3-only
protein Bad and has been found to bind and inhibit Bcl-2, Bcl-w and
Bcl-XL. However, it displays a weak afﬁnity to MCL-1 [142]. Thus
cancer cells that overexpress MCL-1, are resistant to this small
molecule compound. To that end, in a small cell lung cancer model,
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chemotherapeutic agents [143]. Of note, ABT-737 is highly effective
against cancers with elevated expression of Bcl-2 and is an efﬁcient
apoptosis inducer in the presence of Bax and Bak [144].
Another group of BH3 peptides synthesized by Shangary et al. to
mimic Bax andBadBH3domainsdemonstrated effective engagement of
the intrinsic pathway with the release of cyt c, even in Bcl-2 and Bcl-XL
overexpressing cells [145]. BH3 peptides have also been shown to
trigger oligomerization of Bax and Bak, resulting in MOMP and cyt c
release [146]. Though the use of BH3mimetics holdsmuch promise, the
use of BH3 peptides in cancer therapeutics has been limited due their
poor cell permeability, bioavailability, solubility and metabolic stability
in vivo. To address these issues, tagged proteins [147] or proteins with
chemical modiﬁcations [148] have been employed.
6. Concluding remarks
Restoration of cell death pathways via the targeting of mitochon-
drial proteins is an attractive concept that emerged following the
identiﬁcation of the central orchestrators of this pathway. Indeed, this
pathway is frequently impaired in cancer cells and contributes to the
development of resistance to conventional chemotherapy. Several
small molecules, targeted anti/pro-oxidants and antisense oligonu-
cleotides have been designed to activate pro-apoptotic proteins as
well as to block anti-apoptotic proteins and are currently under
clinical evaluation. Results of clinical trials will determinewhether the
promise that these strategies hold will be realized for a signiﬁcant
improvement in the clinical management of cancers that are refrac-
tory to conventional interventions.
Acknowledgments
The work of CB is supported by le Centre National de la Recherche
Scientiﬁque (CNRS), and l'Agence Nationale de la Recherche (ANR,
ANR-08PCVI-0008-01). CB is also supported by l'Institut National pour
le Cancer (INCa, 2008-1-PL BIO-04-CNS ON1) and l'Université Paris
Sud (Programme Attractivité). S.P is supported by research grants
from the Biomedical Research Council of Singapore, the National
Medical Research Council of Singapore, Singapore Cancer Syndicate,
Ministry of Education (Tier 2) Singapore, Cancer and Stem Cell Biology
program of Duke-NUS Graduate Medical School, Singapore, and the
Experimental Therapeutics Program within the Cancer Sciences
Institute, NUHS, Singapore.
References
[1] M.D. Jacobson, M. Weil, M.C. Raff, Programmed cell death in animal develop-
ment, Cell 88 (1997) 347–354.
[2] D. Hanahan, R.A. Weinberg, The hallmarks of cancer, Cell 100 (2000) 57–70.
[3] M. Zornig, A. Hueber, W. Baum, G. Evan, Apoptosis regulators and their role in
tumorigenesis, Biochim. Biophys. Acta 1551 (2001) F1–F37.
[4] S. Fulda, L. Galluzzi, G. Kroemer, Targeting mitochondria for cancer therapy, Nat.
Rev. Drug Discov. 9 (2010) 447–464.
[5] J.F. Kerr, A.H. Wyllie, A.R. Currie, Apoptosis: a basic biological phenomenon with
wide-ranging implications in tissue kinetics, Br. J. Cancer 26 (1972) 239–257.
[6] N.N. Danial, S.J. Korsmeyer, Cell death: critical control points, Cell 116 (2004)
205–219.
[7] H. Vakifahmetoglu-Norberg, B. Zhivotovsky, The unpredictable caspase-2: what
can it do? Trends Cell Biol. 20 (2010) 150–159.
[8] C. Scafﬁdi, S. Fulda, A. Srinivasan, C. Friesen, F. Li, K.J. Tomaselli, K.M. Debatin, P.H.
Krammer, M.E. Peter, Two CD95 (APO-1/Fas) signaling pathways, EMBO J. 17
(1998) 1675–1687.
[9] A. Ashkenazi, V.M. Dixit, Death receptors: signaling and modulation, Science 281
(1998) 1305–1308.
[10] M.O. Hengartner, The biochemistry of apoptosis, Nature 407 (2000) 770–776.
[11] S. Elmore, Apoptosis: a review of programmed cell death, Toxicol. Pathol. 35
(2007) 495–516.
[12] D.R. Schultz,W.J. Harrington Jr., Apoptosis: programmed cell death at amolecular
level, Semin. Arthritis Rheum. 32 (2003) 345–369.
[13] C.M. Rudin, C.B. Thompson, Apoptosis and disease: regulation and clinical
relevance of programmed cell death, Annu. Rev. Med. 48 (1997) 267–281.[14] L. Fesus, P.J. Davies, M. Piacentini, Apoptosis: molecular mechanisms in
programmed cell death, Eur. J. Cell Biol. 56 (1991) 170–177.
[15] A. Gross, J.M. McDonnell, S.J. Korsmeyer, BCL-2 family members and the
mitochondria in apoptosis, Genes Dev. 13 (1999) 1899–1911.
[16] E.A. Slee,M.T. Harte, R.M. Kluck, B.B.Wolf, C.A. Casiano, D.D.Newmeyer, H.G.Wang,
J.C. Reed, D.W. Nicholson, E.S. Alnemri, D.R. Green, S.J. Martin, Ordering the
cytochromec-initiated caspase cascade: hierarchical activationof caspases-2, -3, -6,
-7, -8, and -10 in a caspase-9-dependent manner, J. Cell Biol. 144 (1999) 281–292.
[17] N. Joza, S.A. Susin, E. Daugas,W.L. Stanford, S.K. Cho, C.Y. Li, T. Sasaki, A.J. Elia, H.Y.
Cheng, L. Ravagnan, K.F. Ferri, N. Zamzami, A.Wakeham, R. Hakem, H. Yoshida, Y.Y.
Kong, T.W. Mak, J.C. Zuniga-Pﬂucker, G. Kroemer, J.M. Penninger, Essential role of
themitochondrial apoptosis-inducing factor in programmed cell death, Nature 410
(2001) 549–554.
[18] A.B. Alvero, M.K. Montagna, R. Chen, K.H. Kim, K. Kyungjin, I. Visintin, H.H. Fu, D.
Brown,G.Mor,NV-128, a novel isoﬂavonederivative, induces caspase-independent
cell death through the Akt/mammalian target of rapamycin pathway, Cancer 115
(2009) 3204–3216.
[19] H. Boujrad, O. Gubkina, N. Robert, S. Krantic, S.A. Susin, AIF-mediated programmed
necrosis: a highly regulated way to die, Cell Cycle 6 (2007) 2612–2619.
[20] Y. Tsujimoto, L.R. Finger, J. Yunis, P.C. Nowell, C.M. Croce, Cloning of the
chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome
translocation, Science 226 (1984) 1097–1099.
[21] S. Cory, J.M. Adams, The Bcl2 family: regulators of the cellular life-or-death
switch, Nat. Rev. Cancer 2 (2002) 647–656.
[22] C. Brenner, H. Cadiou, H.L. Vieira, N. Zamzami, I. Marzo, Z. Xie, B. Leber, D.
Andrews, H. Duclohier, J.C. Reed, G. Kroemer, Bcl-2 and Bax regulate the channel
activity of the mitochondrial adenine nucleotide translocator, Oncogene 19
(2000) 329–336.
[23] Z.X. Chen, S. Pervaiz, Bcl-2 induces pro-oxidant state by engaging mitochondrial
respiration in tumor cells, Cell Death Differ. 14 (2007) 1617–1627.
[24] M.Y. Vyssokikh, L. Zorova, D. Zorov, G. Heimlich, J.J. Jurgensmeier, D. Brdiczka,
Bax releases cytochrome c preferentially from a complex between porin and
adenine nucleotide translocator Hexokinase activity suppresses this effect, Mol
Biol Rep 29 (2002) 93–96.
[25] I. Marzo, C. Brenner, N. Zamzami, J.M. Jurgensmeier, S.A. Susin, H.L. Vieira, M.C.
Prevost, Z. Xie, S. Matsuyama, J.C. Reed, G. Kroemer, Bax and adenine nucleotide
translocator cooperate in the mitochondrial control of apoptosis, Science 281
(1998) 2027–2031.
[26] E. Yang, J. Zha, J. Jockel, L.H. Boise, C.B. Thompson, S.J. Korsmeyer, Bad, a
heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell
death, Cell 80 (1995) 285–291.
[27] J.C. Reed, Bcl-2 family proteins, Oncogene 17 (1998) 3225–3236.
[28] M.J. Birnbaum, R.J. Clem, L.K. Miller, An apoptosis-inhibiting gene from a nuclear
polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs, J. Virol.
68 (1994) 2521–2528.
[29] C.S. Duckett, V.E. Nava, R.W. Gedrich, R.J. Clem, J.L. Van Dongen, M.C. Gilﬁllan, H.
Shiels, J.M. Hardwick, C.B. Thompson, A conserved family of cellular genes
related to the baculovirus iap gene and encoding apoptosis inhibitors, EMBO J. 15
(1996) 2685–2694.
[30] C.S. Duckett, IAP proteins: sticking it to Smac, Biochem. J. 385 (2005) e1–e2.
[31] D.P. Lane, Cancer. p53, guardian of the genome, Nature 358 (1992) 15–16.
[32] L. Chen, D.M. Gilkes, Y. Pan, W.S. Lane, J. Chen, ATM and Chk2-dependent
phosphorylation of MDMX contribute to p53 activation after DNA damage,
EMBO J. 24 (2005) 3411–3422.
[33] R. Maya, M. Balass, S.T. Kim, D. Shkedy, J.F. Leal, O. Shifman, M. Moas, T.
Buschmann, Z. Ronai, Y. Shiloh, M.B. Kastan, E. Katzir, M. Oren, ATM-dependent
phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage,
Genes Dev. 15 (2001) 1067–1077.
[34] F. Zindy, C.M. Eischen, D.H. Randle, T. Kamijo, J.L. Cleveland, C.J. Sherr, M.F.
Roussel, Myc signaling via the ARF tumor suppressor regulates p53-dependent
apoptosis and immortalization, Genes Dev. 12 (1998) 2424–2433.
[35] S. Hong, R.V. Pusapati, J.T. Powers, D.G. Johnson, Oncogenes and the DNA damage
response: Myc and E2F1 engage the ATM signaling pathway to activate p53 and
induce apoptosis, Cell Cycle 5 (2006) 801–803.
[36] U.M. Moll, S. Wolff, D. Speidel, W. Deppert, Transcription-independent pro-
apoptotic functions of p53, Curr. Opin. Cell Biol. 17 (2005) 631–636.
[37] J. Nakano, C.L. Huang, D. Liu, M. Ueno, S. Sumitomo, H. Yokomise, Survivin gene
expression is negatively regulated by the p53 tumor suppressor gene in non-
small cell lung cancer, Int. J. Oncol. 27 (2005) 1215–1221.
[38] J.I. Leu, P. Dumont, M. Hafey, M.E. Murphy, D.L. George, Mitochondrial p53
activates Bak and causes disruption of a Bak-Mcl1 complex, Nat. Cell Biol. 6
(2004) 443–450.
[39] J.E. Chipuk, D.R. Green, Cytoplasmic p53: bax and forward, Cell Cycle 3 (2004)
429–431.
[40] J.E. Chipuk, T. Kuwana, L. Bouchier-Hayes, N.M. Droin, D.D. Newmeyer, M.
Schuler, D.R. Green, Direct activation of Bax by p53 mediates mitochondrial
membrane permeabilization and apoptosis, Science 303 (2004) 1010–1014.
[41] J.E. Chipuk, U. Maurer, D.R. Green, M. Schuler, Pharmacologic activation of p53
elicits Bax-dependent apoptosis in the absence of transcription, Cancer Cell 4
(2003) 371–381.
[42] M. Schuler, E. Bossy-Wetzel, J.C. Goldstein, P. Fitzgerald, D.R. Green, p53 induces
apoptosis by caspase activation throughmitochondrial cytochrome c release, J. Biol.
Chem. 275 (2000) 7337–7342.
[43] E. Oda, R. Ohki, H. Murasawa, J. Nemoto, T. Shibue, T. Yamashita, T. Tokino, T.
Taniguchi, N. Tanaka, Noxa, a BH3-only member of the Bcl-2 family and
candidate mediator of p53-induced apoptosis, Science 288 (2000) 1053–1058.
744 I.R. Indran et al. / Biochimica et Biophysica Acta 1807 (2011) 735–745[44] F. Murray-Zmijewski, D.P. Lane, J.C. Bourdon, p53/p63/p73 isoforms: an
orchestra of isoforms to harmonise cell differentiation and response to stress,
Cell Death Differ. 13 (2006) 962–972.
[45] M.P. Deyoung, L.W. Ellisen, p63 and p73 in human cancer: deﬁning the network,
Oncogene 26 (2007) 5169–5183.
[46] V. Dotsch, F. Bernassola, D. Coutandin, E. Candi, G. Melino, p63 and p73, the
ancestors of p53, Cold Spring Harb. Perspect. Biol. 2 (2010) a004887.
[47] S.H. Woo, I.C. Park, M.J. Park, S. An, H.C. Lee, H.O. Jin, S.A. Park, H. Cho, S.J. Lee, H.S.
Gwak, Y.J. Hong, S.I. Hong, C.H. Rhee, Arsenic trioxide sensitizes CD95/Fas-induced
apoptosis through ROS-mediated upregulation of CD95/Fas by NF-kappaB
activation, Int. J. Cancer 112 (2004) 596–606.
[48] H.L. Huang, L.W. Fang, S.P. Lu, C.K. Chou, T.Y. Luh, M.Z. Lai, DNA-damaging
reagents induce apoptosis through reactive oxygen species-dependent Fas
aggregation, Oncogene 22 (2003) 8168–8177.
[49] K. Izeradjene, L. Douglas, D.M. Tillman, A.B. Delaney, J.A. Houghton, Reactive
oxygen species regulate caspase activation in tumor necrosis factor-related
apoptosis-inducing ligand-resistant human colon carcinoma cell lines, Cancer
Res. 65 (2005) 7436–7445.
[50] Y.J. Lee, K.H. Lee, H.R. Kim, J.M. Jessup, D.W. Seol, T.H. Kim, T.R. Billiar, Y.K. Song,
Sodium nitroprusside enhances TRAIL-induced apoptosis via a mitochondria-
dependent pathway in human colorectal carcinoma CX-1 cells, Oncogene 20
(2001) 1476–1485.
[51] I.R. Indran, M.P. Hande, S. Pervaiz, Tumor cell redox state and mitochondria at
the center of the non-canonical activity of telomerase reverse transcriptase, Mol.
Aspects Med. 31 (2010) 21–28.
[52] I.R. Indran, M.P. Hande, S. Pervaiz, hTERT overexpression alleviates intracellular
ROS production, improves mitochondrial function, and inhibits ROS-mediated
apoptosis in cancer cells, Cancer Res. 71 (2011) 266–276.
[53] M.V. Clement, S. Pervaiz, Reactive oxygen intermediates regulate cellular response
to apoptotic stimuli: an hypothesis, Free Radic. Res. 30 (1999) 247–252.
[54] S. Pervaiz, J.K. Ramalingam, J.L. Hirpara, M.V. Clement, Superoxide anion inhibits
drug-induced tumor cell death, FEBS Lett. 459 (1999) 343–348.
[55] S. Pervaiz, M.V. Clement, Hydrogen peroxide-induced apoptosis: oxidative or
reductive stress? Methods Enzymol. 352 (2002) 150–159.
[56] S. Pervaiz, M.V. Clement, Tumor intracellular redox status and drug resistance—
serendipity or a causal relationship? Curr. Pharm. Des. 10 (2004) 1969–1977.
[57] S. Pervaiz, M.V. Clement, Superoxide anion: oncogenic reactive oxygen species?
Int. J. Biochem. Cell Biol. 39 (2007) 1297–1304.
[58] S. Akram, H.F. Teong, L. Fliegel, S. Pervaiz, M.V. Clement, Reactive oxygen species-
mediated regulation of the Na+−H+exchanger 1 gene expression connects
intracellular redox status with cells' sensitivity to death triggers, Cell Death
Differ. 13 (2006) 628–641.
[59] A.P. Kumar, M.K. Chang, L. Fliegel, S. Pervaiz, M.V. Clement, Oxidative repression
of NHE1 gene expression involves iron-mediated caspase activity, Cell Death
Differ. 14 (2007) 1733–1746.
[60] J.L. Hirpara, M.V. Clement, S. Pervaiz, Intracellular acidiﬁcation triggered by
mitochondrial-derived hydrogen peroxide is an effector mechanism for drug-
induced apoptosis in tumor cells, J. Biol. Chem. 276 (2001) 514–521.
[61] K.A. Ahmad, K.B. Iskandar, J.L. Hirpara, M.V. Clement, S. Pervaiz, Hydrogen
peroxide-mediated cytosolic acidiﬁcation is a signal for mitochondrial translo-
cation of Bax during drug-induced apoptosis of tumor cells, Cancer Res. 64
(2004) 7867–7878.
[62] P. Costantini, A.S. Belzacq, H.L. Vieira, N. Larochette, M.A. de Pablo, N. Zamzami, S.A.
Susin, C. Brenner, G. Kroemer, Oxidation of a critical thiol residue of the adenine
nucleotide translocator enforces Bcl-2-independent permeability transition pore
opening and apoptosis, Oncogene 19 (2000) 307–314.
[63] M. Madesh, G. Hajnoczky, VDAC-dependent permeabilization of the outer
mitochondrial membrane by superoxide induces rapid and massive cytochrome
c release, J. Cell Biol. 155 (2001) 1003–1015.
[64] E. Migliaccio, M. Giorgio, S. Mele, G. Pelicci, P. Reboldi, P.P. Pandolﬁ, L. Lanfrancone,
P.G. Pelicci, The p66shc adaptor protein controls oxidative stress response and life
span in mammals, Nature 402 (1999) 309–313.
[65] J.C. Reed, Dysregulation of apoptosis in cancer, J. Clin. Oncol. 17 (1999) 2941–2953.
[66] E.J. Schattner, Apoptosis in lymphocytic leukemias and lymphomas, Cancer
Invest. 20 (2002) 737–748.
[67] K. Yamanaka, P. Rocchi, H. Miyake, L. Fazli, A. So, U. Zangemeister-Wittke, M.E.
Gleave, Induction of apoptosis and enhancement of chemosensitivity in human
prostate cancer LNCaP cells using bispeciﬁc antisense oligonucleotide targeting
Bcl-2 and Bcl-xL genes, BJU Int. 97 (2006) 1300–1308.
[68] U. Zangemeister-Wittke, S.H. Leech, R.A. Olie, A.P. Simoes-Wust, O. Gautschi, G.H.
Luedke, F. Natt, R. Haner, P. Martin, J. Hall, C.M. Nalin, R.A. Stahel, A novel bispeciﬁc
antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efﬁciently
induces apoptosis in tumor cells, Clin. Cancer Res. 6 (2000) 2547–2555.
[69] L.C. Cantley, The phosphoinositide 3-kinase pathway, Science 296 (2002)
1655–1657.
[70] O. Micheau, M. Thome, P. Schneider, N. Holler, J. Tschopp, D.W. Nicholson, C.
Briand, M.G. Grutter, The long form of FLIP is an activator of caspase-8 at the Fas
death-inducing signaling complex, J. Biol. Chem. 277 (2002) 45162–45171.
[71] A. Ashkenazi, Targeting death and decoy receptors of the tumour-necrosis factor
superfamily, Nat. Rev. Cancer 2 (2002) 420–430.
[72] S.H. Jeong, H.W. Lee, J.H. Han, S.Y. Kang, J.H. Choi, Y.M. Jung, H. Choi, Y.T. Oh, K.J.
Park, S.C. Hwang, S.S. Sheen, Y.J. Oh, J.H. Kim, H.Y. Lim, Low expression of Bax
predicts poor prognosis in resected non-small cell lung cancer patients with
non-squamous histology, Jpn. J. Clin. Oncol. 38 (2008) 661–669.
[73] M. Schuyer, M.E. van der Burg, S.C. Henzen-Logmans, J.H. Fieret, J.G. Klijn, M.P.
Look, J.A. Foekens, G. Stoter, E.M. Berns, Reduced expression of BAX is associatedwith poor prognosis in patients with epithelial ovarian cancer: a multifactorial
analysis of TP53, p21, BAX and BCL-2, Br. J. Cancer 85 (2001) 1359–1367.
[74] F.A. Sinicrope, R.L. Rego, K. Okumura, N.R. Foster, M.J. O'Connell, D.J. Sargent, H.E.
Windschitl, Prognostic impact of bim, puma, and noxa expression in human
colon carcinomas, Clin. Cancer Res. 14 (2008) 5810–5818.
[75] J. Tschopp, F. Martinon, K. Hofmann, Apoptosis: silencing the death receptors,
Curr. Biol. 9 (1999) R381–R384.
[76] S. Hopkins-Donaldson, R. Cathomas, A.P. Simoes-Wust, S. Kurtz, L. Belyanskaya,
R.A. Stahel, U. Zangemeister-Wittke, Induction of apoptosis and chemosensitiza-
tion of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment, Int. J. Cancer
106 (2003) 160–166.
[77] H. Dixon, C.J. Norbury, Therapeutic exploitation of checkpoint defects in cancer
cells lacking p53 function, Cell Cycle 1 (2002) 362–368.
[78] A. Matheu, A. Maraver, M. Serrano, The Arf/p53 pathway in cancer and aging,
Cancer Res. 68 (2008) 6031–6034.
[79] F. Toledo, G.M. Wahl, MDM2 and MDM4: p53 regulators as targets in anticancer
therapy, Int. J. Biochem. Cell Biol. 39 (2007) 1476–1482.
[80] D. Green, G. Kroemer, The central executioners of apoptosis: caspases or
mitochondria? Trends Cell Biol. 8 (1998) 267–271.
[81] S. Weinhouse, The Warburg hypothesis ﬁfty years later, Z. Krebsforsch. Klin.
Onkol. Cancer Res. Clin. Oncol. 87 (1976) 115–126.
[82] S. Pavlides, D. Whitaker-Menezes, R. Castello-Cros, N. Flomenberg, A.K.
Witkiewicz, P.G. Frank, M.C. Casimiro, C. Wang, P. Fortina, S. Addya, R.G. Pestell,
U.E. Martinez-Outschoorn, F. Sotgia, M.P. Lisanti, The reverse Warburg effect:
aerobic glycolysis in cancer associated ﬁbroblasts and the tumor stroma, Cell
Cycle 8 (2009) 3984–4001.
[83] M. Lopez-Lazaro, The warburg effect: why and how do cancer cells activate
glycolysis in the presence of oxygen? Anticancer Agents Med. Chem. 8 (2008)
305–312.
[84] K. Newell, A. Franchi, J. Pouyssegur, I. Tannock, Studies with glycolysis-deﬁcient
cells suggest that production of lactic acid is not the only cause of tumor acidity,
Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 1127–1131.
[85] L. Schrevens, N. Lorent, C. Dooms, J. Vansteenkiste, The role of PET scan in
diagnosis, staging, and management of non-small cell lung cancer, Oncologist 9
(2004) 633–643.
[86] J.M. Cuezva,M. Krajewska, M.L. de Heredia, S. Krajewski, G. Santamaria, H. Kim, J.M.
Zapata, H. Marusawa, M. Chamorro, J.C. Reed, The bioenergetic signature of cancer:
a marker of tumor progression, Cancer Res. 62 (2002) 6674–6681.
[87] J.M. Cuezva, G. Chen, A.M. Alonso, A. Isidoro, D.E. Misek, S.M. Hanash, D.G. Beer,
The bioenergetic signature of lung adenocarcinomas is a molecular marker of
cancer diagnosis and prognosis, Carcinogenesis 25 (2004) 1157–1163.
[88] J.G. Pastorino, N. Shulga, J.B. Hoek, Mitochondrial binding of hexokinase II
inhibits Bax-induced cytochrome c release and apoptosis, J. Biol. Chem. 277
(2002) 7610–7618.
[89] P. Kakkar, B.K. Singh, Mitochondria: a hub of redox activities and cellular distress
control, Mol. Cell. Biochem. 305 (2007) 235–253.
[90] D.J. Betteridge, What is oxidative stress? Metabolism 49 (2000) 3–8.
[91] S. Orrenius, Reactive oxygen species in mitochondria-mediated cell death, Drug
Metab. Rev. 39 (2007) 443–455.
[92] S.J. Ralph, S. Rodriguez-Enriquez, J. Neuzil, E. Saavedra, R. Moreno-Sanchez, The
causes of cancer revisited: “mitochondrial malignancy” and ROS-induced
oncogenic transformation—why mitochondria are targets for cancer therapy,
Mol. Aspects Med. 31 (2010) 145–170.
[93] V. Maximo, M. Sobrinho-Simoes, Hurthle cell tumours of the thyroid. A review
with emphasis on mitochondrial abnormalities with clinical relevance, Virchows
Arch 437 (2000) 107–115.
[94] P.L. Pedersen, Tumor mitochondria and the bioenergetics of cancer cells, Prog.
Exp. Tumor Res. 22 (1978) 190–274.
[95] J.S. Modica-Napolitano, J.R. Aprille, Delocalized lipophilic cations selectively
target the mitochondria of carcinoma cells, Adv. Drug Deliv. Rev. 49 (2001)
63–70.
[96] H.A. Coller, K. Khrapko, N.D. Bodyak, E. Nekhaeva, P. Herrero-Jimenez, W.G.
Thilly, High frequency of homoplasmic mitochondrial DNA mutations in human
tumors can be explained without selection, Nat. Genet. 28 (2001) 147–150.
[97] M.S. Fliss, H. Usadel, O.L. Caballero, L. Wu, M.R. Buta, S.M. Eleff, J. Jen, D.
Sidransky, Facile detection of mitochondrial DNA mutations in tumors and
bodily ﬂuids, Science 287 (2000) 2017–2019.
[98] A.W. Dobson, M.R. Kelley, G.L. Wilson, S.P. LeDoux, Targeting DNA repair
proteins to mitochondria, Methods Mol. Biol. 197 (2002) 351–362.
[99] A.W. Dobson, Y. Xu, M.R. Kelley, S.P. LeDoux, G.L. Wilson, Enhanced mitochon-
drial DNA repair and cellular survival after oxidative stress by targeting the
human 8-oxoguanine glycosylase repair enzyme to mitochondria, J. Biol. Chem.
275 (2000) 37518–37523.
[100] N. Raghunand, X. He, R. van Sluis, B. Mahoney, B. Baggett, C.W. Taylor, G. Paine-
Murrieta, D. Roe, Z.M. Bhujwalla, R.J. Gillies, Enhancement of chemotherapy by
manipulation of tumour pH, Br. J. Cancer 80 (1999) 1005–1011.
[101] N. Raghunand, R. Martinez-Zaguilan, S.H. Wright, R.J. Gillies, pH and drug
resistance. II. Turnover of acidic vesicles and resistance to weakly basic
chemotherapeutic drugs, Biochem. Pharmacol. 57 (1999) 1047–1058.
[102] T. Uwagawa, T. Misawa, T. Iida, T. Sakamoto, T. Gocho, S. Wakiyama, S. Hirohara,
K. Yanaga, Proton-pump inhibitor as palliative care for chemotherapy-induced
gastroesophageal reﬂux disease in pancreatic cancer patients, J. Palliat. Med. 13
(2010) 815–818.
[103] M. Yeo, D.K. Kim, H.J. Park, S.W. Cho, J.Y. Cheong, K.J. Lee, Blockage of intracellular
proton extrusion with proton extrusions with proton pump inhibitor induces
apoptosis in gastric cancer, Cancer Sci. 99 (2008) 185.
745I.R. Indran et al. / Biochimica et Biophysica Acta 1807 (2011) 735–745[104] I. Ben Sahra, K. Laurent, S. Giuliano, F. Larbret, G. Ponzio, P. Gounon, Y. Le
Marchand-Brustel, S. Giorgetti-Peraldi, M. Cormont, C. Bertolotto, M. Deckert, P.
Auberger, J.F. Tanti, F. Bost, Targeting cancer cell metabolism: the combination of
metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate
cancer cells, Cancer Res. 70 (2010) 2465–2475.
[105] A. Floridi, M.G. Paggi, S. D'Atri, C. De Martino, M.L. Marcante, B. Silvestrini, A.
Caputo, Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor
cells, Cancer Res. 41 (1981) 4661–4666.
[106] A. Floridi, M.G. Paggi, M.L. Marcante, B. Silvestrini, A. Caputo, C. De Martino,
Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells,
J. Natl. Cancer Inst. 66 (1981) 497–499.
[107] M. De Lena, V. Lorusso, A. Latorre, G. Fanizza, G. Gargano, L. Caporusso, M.
Guida, A. Catino, E. Crucitta, D. Sambiasi, A. Mazzei, Paclitaxel, cisplatin and
lonidamine in advanced ovarian cancer. A phase II study, Eur. J. Cancer 37 (2001)
364–368.
[108] L. Miccoli, F. Poirson-Bichat, F. Sureau, R. Bras Goncalves, Y. Bourgeois, B.
Dutrillaux, M.F. Poupon, S. Oudard, Potentiation of lonidamine and diazepam,
two agents acting on mitochondria, in human glioblastoma treatment, J. Natl.
Cancer Inst. 90 (1998) 1400–1406.
[109] U. Gatzemeier, F. Cavalli, K. Haussinger, E. Kaukel, G. Koschel, G. Martinelli, R.
Neuhauss, J. von Pawel, Phase III trial with and without lonidamine in non-small
cell lung cancer, Semin. Oncol. 18 (1991) 42–48.
[110] H. Pelicano, L. Feng, Y. Zhou, J.S. Carew, E.O. Hileman, W. Plunkett, M.J. Keating, P.
Huang, Inhibition of mitochondrial respiration: a novel strategy to enhance
drug-induced apoptosis in human leukemia cells by a reactive oxygen species-
mediated mechanism, J. Biol. Chem. 278 (2003) 37832–37839.
[111] K. Shenoy, Y. Wu, S. Pervaiz, LY303511 enhances TRAIL sensitivity of SHEP-1
neuroblastoma cells via hydrogen peroxide-mediatedmitogen-activated protein
kinase activation and up-regulation of death receptors, Cancer Res. 69 (2009)
1941–1950.
[112] T.W. Poh, S. Huang, J.L. Hirpara, S. Pervaiz, LY303511 ampliﬁes TRAIL-induced
apoptosis in tumor cells by enhancing DR5 oligomerization DISC assembly, and
mitochondrial permeabilization, Cell Death Differ 14 (2007) 1813–1825.
[113] C.H. Wong, K.B. Iskandar, S.K. Yadav, J.L. Hirpara, T. Loh, S. Pervaiz, Simultaneous
induction of non-canonical autophagy and apoptosis in cancer cells by ROS-
dependent ERK and JNK activation, PLoS One 5 (2010) e9996.
[114] Z. Jhumka, S. Pervaiz, M.V. Clement, Resveratrol regulates the expression of NHE-1
by repressing its promoter activity: critical involvement of intracellular H2O2 and
caspases 3 and 6 in the absence of cell death, Int. J. Biochem. Cell Biol. 41 (2009)
945–956.
[115] E.D. Michelakis, G. Sutendra, P. Dromparis, L. Webster, A. Haromy, E. Niven, C.
Maguire, T.L. Gammer, J.R. Mackey, D. Fulton, B. Abdulkarim, M.S. McMurtry, K.C.
Petruk, Metabolic modulation of glioblastoma with dichloroacetate, Sci. Transl.
Med. 2 (2010) 31ra34.
[116] K. Henze, W. Martin, Evolutionary biology: essence of mitochondria, Nature 426
(2003) 127–128.
[117] G. Kroemer, L. Galluzzi, C. Brenner, Mitochondrial membrane permeabilization
in cell death, Physiol. Rev. 87 (2007) 99–163.
[118] S. Desagher, J.C. Martinou, Mitochondria as the central control point of apoptosis,
Trends Cell Biol. 10 (2000) 369–377.
[119] P. Mitchell, J. Moyle, Stoichiometry of proton translocation through the respiratory
chain and adenosine triphosphatase systems of rat liver mitochondria, Nature 208
(1965) 147–151.
[120] J.S. Modica-Napolitano, R. Nalbandian, M.E. Kidd, A. Nalbandian, C.C. Nguyen, The
selective in vitro cytotoxicity of carcinoma cells by AZT is enhanced by concurrent
treatment with delocalized lipophilic cations, Cancer Lett. 198 (2003) 59–68.
[121] K. Koya, Y. Li, H. Wang, T. Ukai, N. Tatsuta, M. Kawakami, T. Shishido, L.B. Chen,
MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma
activity in preclinical studies based on selective mitochondrial accumulation,
Cancer Res. 56 (1996) 538–543.
[122] A.P. Halestrap, C. Brenner, The adenine nucleotide translocase: a central
component of the mitochondrial permeability transition pore and key player
in cell death, Curr. Med. Chem. 10 (2003) 1507–1525.
[123] M. Zoratti, I. Szabo, The mitochondrial permeability transition, Biochim. Biophys.
Acta 1241 (1995) 139–176.
[124] T. Azarashvili, D. Grachev, O. Krestinina, Y. Evtodienko, I. Yurkov, V. Papado-
poulos, G. Reiser, The peripheral-type benzodiazepine receptor is involved in
control of Ca2+-induced permeability transition pore opening in rat brain
mitochondria, Cell Calcium 42 (2007) 27–39.
[125] M. Crompton, The mitochondrial permeability transition pore and its role in cell
death, Biochem. J. 341 (Pt 2) (1999) 233–249.
[126] H. Faure Vigny, A. Heddi, S. Giraud, D. Chautard, G. Stepien, Expression of
oxidative phosphorylation genes in renal tumors and tumoral cell lines, Mol.
Carcinog. 16 (1996) 165–172.
[127] C.V. Dang, G.L. Semenza, Oncogenic alterations of metabolism, Trends Biochem.
Sci. 24 (1999) 68–72.[128] M.M. Katabi, H.L. Chan, S.E. Karp, G. Batist, Hexokinase type II: a novel tumor-
speciﬁc promoter for gene-targeted therapy differentially expressed and
regulated in human cancer cells, Hum. Gene Ther. 10 (1999) 155–164.
[129] C. Brenner, K. Subramaniam, C. Pertuiset, S. Pervaiz, Adenine nucleotide
translocase family: four isoforms for apoptosis modulation in cancer, Oncogene.
[130] K. Machida, Y. Hayashi, H. Osada, A novel adenine nucleotide translocase
inhibitor, MT-21, induces cytochrome c release by a mitochondrial permeability
transition-independent mechanism, J. Biol. Chem. 277 (2002) 31243–31248.
[131] N. Takai, T. Ueda, M. Nishida, K. Nasu, H. Narahara, PK11195 enhances chemo-
sensitivity to cisplatin and paclitaxel in human endometrial and ovarian cancer
cells, Int. J. Mol. Med. 25 (2010) 97–103.
[132] N. Zamzami, C. Maisse, D. Metivier, G. Kroemer, Measurement of membrane
permeability and permeability transition of mitochondria, Methods Cell Biol. 65
(2001) 147–158.
[133] Y. Shi, J. Chen, C. Weng, R. Chen, Y. Zheng, Q. Chen, H. Tang, Identiﬁcation of the
protein-protein contact site and interaction mode of human VDAC1 with Bcl-2
family proteins, Biochem. Biophys. Res. Commun. 305 (2003) 989–996.
[134] S. Shimizu, M. Narita, Y. Tsujimoto, Bcl-2 family proteins regulate the release of
apoptogenic cytochrome c by the mitochondrial channel VDAC, Nature 399
(1999) 483–487.
[135] F. Manero, F. Gautier, T. Gallenne, N. Cauquil, D. Gree, P.F. Cartron, O. Geneste, R.
Gree, F.M. Vallette, P. Juin, The small organic compound HA14-1 prevents Bcl-2
interaction with Bax to sensitize malignant glioma cells to induction of cell
death, Cancer Res. 66 (2006) 2757–2764.
[136] L. Oliver, B. Mahe, R. Gree, F.M. Vallette, P. Juin, HA14-1, a small molecule
inhibitor of Bcl-2, bypasses chemoresistance in leukaemia cells, Leuk. Res. 31
(2007) 859–863.
[137] M. Pellecchia, J.C. Reed, Inhibition of anti-apoptotic Bcl-2 family proteins by
natural polyphenols: new avenues for cancer chemoprevention and chemo-
therapy, Curr. Pharm. Des. 10 (2004) 1387–1398.
[138] R.M. Mohammad, S. Wang, S. Banerjee, X. Wu, J. Chen, F.H. Sarkar, Nonpeptidic
small-molecule inhibitor of Bcl-2 and Bcl-XL, (−)-Gossypol, enhances biological
effect of genistein against BxPC-3 human pancreatic cancer cell line, Pancreas 31
(2005) 317–324.
[139] J.A. Bauer, D.K. Trask, B.Kumar, G. Los, J. Castro, J.S. Lee, J. Chen, S.Wang, C.R. Bradford,
T.E. Carey, Reversal of cisplatin resistancewith a BH3mimetic, (−)-gossypol, in head
and neck cancer cells: role of wild-type p53 and Bcl-xL, Mol. Cancer Ther. 4 (2005)
1096–1104.
[140] L. Xu, D. Yang, S. Wang, W. Tang, M. Liu, M. Davis, J. Chen, J.M. Rae, T. Lawrence,
M.E. Lippman, (−)-Gossypol enhances response to radiation therapy and results
in tumor regression of human prostate cancer, Mol. Cancer Ther. 4 (2005)
197–205.
[141] A.Y. Bedikian, M. Millward, H. Pehamberger, R. Conry, M. Gore, U. Trefzer, A.C.
Pavlick, R.DeConti, E.M.Hersh, P.Hersey, J.M.Kirkwood, F.G.Haluska, Bcl-2antisense
(oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the
Oblimersen Melanoma Study Group, J. Clin. Oncol. 24 (2006) 4738–4745.
[142] M.F. van Delft, A.H. Wei, K.D. Mason, C.J. Vandenberg, L. Chen, P.E. Czabotar, S.N.
Willis, C.L. Scott, C.L. Day, S. Cory, J.M. Adams, A.W. Roberts, D.C. Huang, The BH3
mimetic ABT-737 targets selective Bcl-2 proteins and efﬁciently induces
apoptosis via Bak/Bax if Mcl-1 is neutralized, Cancer Cell 10 (2006) 389–399.
[143] T. Oltersdorf, S.W. Elmore, A.R. Shoemaker, R.C. Armstrong, D.J. Augeri, B.A. Belli,
M. Bruncko, T.L. Deckwerth, J. Dinges, P.J. Hajduk, M.K. Joseph, S. Kitada, S.J.
Korsmeyer, A.R. Kunzer, A. Letai, C. Li, M.J. Mitten, D.G. Nettesheim, S. Ng, P.M.
Nimmer, J.M. O'Connor, A. Oleksijew, A.M. Petros, J.C. Reed, W. Shen, S.K. Tahir, C.B.
Thompson, K.J. Tomaselli, B. Wang, M.D. Wendt, H. Zhang, S.W. Fesik, S.H.
Rosenberg, An inhibitor of Bcl-2 family proteins induces regression of solid
tumours, Nature 435 (2005) 677–681.
[144] M. Konopleva, R. Contractor, T. Tsao, I. Samudio, P.P. Ruvolo, S. Kitada, X. Deng, D.
Zhai, Y.X. Shi, T. Sneed, M. Verhaegen, M. Soengas, V.R. Ruvolo, T. McQueen, W.D.
Schober, J.C. Watt, T. Jiffar, X. Ling, F.C. Marini, D. Harris, M. Dietrich, Z. Estrov, J.
McCubrey, W.S. May, J.C. Reed, M. Andreeff, Mechanisms of apoptosis sensitivity
and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia, Cancer
Cell 10 (2006) 375–388.
[145] S. Shangary, D.E. Johnson, Peptides derived from BH3 domains of Bcl-2 family
members: a comparative analysis of inhibition of Bcl-2, Bcl-x(L) and Bax
oligomerization, induction of cytochrome c release, and activation of cell death,
Biochemistry 41 (2002) 9485–9495.
[146] T. Kuwana, L. Bouchier-Hayes, J.E. Chipuk, C. Bonzon, B.A. Sullivan, D.R. Green, D.D.
Newmeyer, BH3 domains of BH3-only proteins differentially regulate Bax-
mediated mitochondrial membrane permeabilization both directly and indirectly,
Mol. Cell 17 (2005) 525–535.
[147] C. Denicourt, S.F. Dowdy, Medicine Targeting apoptotic pathways in cancer cells,
Science 305 (2004) 1411–1413.
[148] L.D. Walensky, A.L. Kung, I. Escher, T.J. Malia, S. Barbuto, R.D. Wright, G. Wagner,
G.L. Verdine, S.J. Korsmeyer, Activation of apoptosis in vivo by a hydrocarbon-
stapled BH3 helix, Science 305 (2004) 1466–1470.
